Neurocrine Biosciences, Inc. (NBIX)
Chart Events
Performance Outlook
| Previous Close | 95.00 |
| Open | 96.42 |
| Bid | 96.45 x 1800 |
| Ask | 98.00 x 1000 |
| Day's Range | 94.61 - 96.89 |
| 52 Week Range | 86.02 - 136.26 |
| Volume | 571,000 |
| Avg. Volume | 1,222,775 |
| Market Cap | 9.13B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | 23.22 |
| EPS (TTM) | 4.16 |
| Earnings Date | May 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 29, 1995 |
| 1y Target Est | 127.38 |
Fair Value
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Pfizer Inc.
- PR Newswire
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines.
- PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
- PR Newswire
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.
